Nanovaccine-based immuno-gene therapy for reprogramming tumor-associated dendritic cells in vivo
文献类型：会议论文
| 作者 | Yifan. Ma; Lanlan Liu; Ce Wang; Hong Pan; Ping Li |
| 出版日期 | 2015 |
| 会议名称 | 第十届全国免疫学学术大会 |
| 会议地点 | 中国北京会议中心 |
| 英文摘要 | Immunosuppressive tumor-associated dendritic cells (TADCs) are a major obstacle for developing effective cancer vaccines. However, reprogramming TADCs in vivo remains difficult due to their poor responsiveness to TLR stimulation. Herein, we identify a dysregulated miR-148a/DNMT1/SOCS1 axis as a unique mechanism for dampened TLR3 stimulation in TADCs, in which tumor-elevated miR-148a up-regulates immunosuppressor SOCS1 through targeting DNMT1, thereby abolishing TLR3-induced TADC maturation. However, targeting miR-148a with miR-148a inhibitor (miR-148ai) effectively recovers the sensitivity of TADCs to TLR3 stimulation through modulating the miR-148a/DNMT1/SOCS1 axis. More importantly, the codelivery of miR-148ai and poly I:C (TLR3 agonist) with nanovaccine not only synergistically promotes TADC maturation in vivo, but also ameliorated tumor immunosuppression, thereby leading to robust anti-cancer immunity and dramatic tumor suppression. This study proposes a nanovaccine-based immuno-gene therapy with the integration of miR-148a inhibition and TLR3 stimulation as a novel therapeutic approach to boost anti-cancer immunity by reprogramming TADCs in vivo. |
| 收录类别 | 其他 |
| 语种 | 英语 |
| 源URL | [http://ir.siat.ac.cn:8080/handle/172644/7425]  |
| 专题 | 深圳先进技术研究院_医药所 |
| 作者单位 | 2015 |
| 推荐引用方式 GB/T 7714 | Yifan. Ma,Lanlan Liu,Ce Wang,et al. Nanovaccine-based immuno-gene therapy for reprogramming tumor-associated dendritic cells in vivo[C]. 见:第十届全国免疫学学术大会. 中国北京会议中心. |
入库方式： OAI收割
来源：深圳先进技术研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。